MaxCyte (MXCT) Stifel 2024 Healthcare Conference summary

Market overview and technology trends

• Cell and gene therapy is rapidly evolving, with a shift from viral to non-viral and ex vivo approaches due to increasing complexity and safety needs.

• Electroporation is gaining momentum as the preferred method for multiple cell edits, supporting more advanced therapies.

• The market consists of about 2,100 programs, with 1,200 in the clinic and 150 companies active in cell and gene therapy.

• Non-viral ex vivo engineering now represents a growing share of the market, driven by demand for safer and more flexible solutions.

Financial performance and revenue drivers

• Cell therapy revenues increased by 40%, reflecting strong activity and improved funding in 2024 after a challenging 2023.

• Q4 is expected to be healthy, with a conservative approach to guidance and growing confidence in exceeding targets.

• Most instrument placements are sales, but leasing is increasing, especially among strategic partners.

• Drug discovery revenue remains stable, with growth mainly driven by cell therapy customers.

Strategic platform licenses (SPLs) and growth outlook

• SPLs provide recurring revenue through licenses, system use, and royalties, with 29 partners currently in the clinic.

• Six SPLs were added in 2024, above the typical annual guidance, setting up for future growth.

• Revenue from SPLs is expected to become less lumpy as more programs mature and reach commercial stages.

• The potential milestone value from SPLs has grown to around $2 billion, reflecting expanded opportunities.